Skip to Main Content


Skip Nav Destination

Bylaws Amendments Expand Role of International Members in Society’s Governance

December 30, 2021

On December 8, 2015, ASH Active members in good standing passed two bylaws amendments during a historic in-person vote at the 57th ASH Annual Meeting to recognize the increasing role that non-North-American hematologists play in contributing to ASH's success. The first gives International members the right to vote and hold Councillor positions, while the second creates a new membership category for international trainees that will allow them to enjoy a benefits package similar to Associate members in North America.

With roughly half of all annual meeting attendees, scientific abstracts, and Blood manuscripts coming from outside of North America, the Society's leadership recognized the importance of providing this group with a greater voice in the decisions that will have an impact on the Society's future.

As 2015 ASH President Dr. David Williams wrote in his President's Column in the July/August 2015 issue of The Hematologist, "For ASH to attract the best science to the annual meeting and Blood, improve the care of patients with blood diseases around the world, and promote international research collaborations, the officers and Executive Committee feel that it is critical for the Society to evolve as a global society. By that I mean that the context in which we develop, deliver, and evaluate our programs and services need to reflect the reality of our global strengths." At the same time he reiterated the leadership's commitment that "funding for current programs, including all our advocacy and educational efforts in North America, will not be reduced in order to fund new international programs or member benefits."

The new International Associate member category provides a discounted rate for hematologists in training outside of North America. You are eligible to apply if you are a post-doctoral fellow with an MD or equivalent medical degree, reside outside of Canada, Mexico, or the United States, and are enrolled in an approved hematology or oncology training program or medical school, or are a student who has a PhD or its equivalent, resides outside of Canada, Mexico, or the United States of America, and are in a post-doctoral position or training program in a hematology and/or hematology-oncology related field. The annual membership fee is $55. For more information, go to

Translational Research Training in Hematology 2015 Class Announced

Translational Research Training in Hematology (TRTH) provides junior researchers with a unique, year-long training and mentoring experience. The program is a joint effort of the European Hematology Association (EHA) and the American Society of Hematology (ASH) and is focused on helping early-career scientists build successful careers in hematologic translational research. It is a year-long course, beginning with an intensive week-long course held in the spring.

The 2015 spring course will be held from March 11-18, 2016 in the Southern part of Europe. Mornings are dedicated to didactic and interactive sessions which further trainees understanding of translational research methodology and regulatory requirements. Afternoons are devoted to small group sessions in which trainees meet with their TRTH mentors, peers, and faculty to refine their individual research proposals. Informal presentations by leaders in hematology, designed to illustrate the variety of pathways to a successful career in hematology research, take place in the evenings.

Twenty early-career scientists are selected each year to participate in this rigorous training program. The TRTH faculty is made up of international leaders in hematology who cover biostatistics and biomarkers, genetics and molecular biology, ethics, and phase I clinical study design. The list of 20 participants are below.

  • Elliot Stieglitz, MD
    University of California, San Francisco
  • Chun-Wei Chen, PhD
    Memorial Sloan Kettering Cancer Center
  • Bas Wouters, MD, PhD
    Erasmus Medical Center
  • Gregory Behbehani, MD, PhD
    The Ohio State University
  • Raphael Itzykson, MD, PhD
    Hopital Saint-Louis, Université Paris Diderot
  • Chun Yew Fong, MD
    Peter MacCallum Cancer Centre
  • Dalia Elgamal, PhD
    The Ohio State University
  • Iris Uras, PhD
    Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna
  • Jyoti Nangalia, MBBChir
    University of Cambridge
  • Alexander Höllein, MD
    Technical University Munich
  • Kate Markey, MBBS, PhD
    The Royal Brisbane and Women's Hospital
  • Mark Murakami, MD
    Dana-Farber Cancer Institute
  • Karen De Ceunynck, PhD
    Beth Israel Deaconess Medical Center
  • Janghee Woo, MD, PhD
    University of Washington/Fred Hutchinson Cancer Research Center
  • Elodie Pronier, PhD
    Memorial Sloan Kettering Cancer Center
  • Robert Kridel, MD
    BC Cancer Agency
  • Melinda Biernacki, MD
    University of Washington/Fred Hutchinson Cancer Research Center
  • Mireya Paulina Velasquez, MD
    Baylor College of Medicine
  • Suthesh Sivapalaratnam, MD
    University of Cambridge
  • Elisa ten Hacken, PhD
    University of Texas MD Anderson Cancer Center

Introducing ASH Compass

ASH Compass is a new training program for biopharmaceutical representatives that benefits the Society's members and the corporate community. The program is designed to educate sales representatives and medical science liaisons (MSLs) about hematologic disorders so they are better prepared to answer clinicians' questions about the hematology products they represent. While pharmaceutical representatives and MSLs are well trained internally about their products, they may lack insight into physicians' concerns and their patients' questions about treatment options.

"The goal is to get the right drug to the right patient for the right indication, and this new program will help facilitate this by educating pharmaceutical representatives about the field of hematology and raising the level of discourse that can occur between clinicians and pharmaceutical companies," Richard Larson, MD, head of the ASH Compass Working Group, which has governance responsibility for the program, said.

The training program includes a pre-test and post-test to assess knowledge gained with a passing score earning an ASH completion indicia that may be used by the learner on a business card. ASH will promote the value of program completion to its members and create measurements of the program's effectiveness with ASH members.

Program Highlights:

  • Live customized unbranded program framed around the patient journey from diagnosis to disease management
  • Clinical thought leaders and subject matter experts create and deliver the training
  • Evidence-based clinical practice guidelines and consensus statements
  • An interactive experiential learning format including case studies and role playing
  • Training results that are tracked and measured

Look for more information in the coming months.


Connect with us:

September 2022


Close Modal

or Create an Account

Close Modal
Close Modal